AI-powered, contact-free imaging that reveals real-time blood flow across diverse vascular and anastomotic surgeries — replacing guesswork with clarity, and giving surgeons what no tool has offered before.
In 2026, surgeons performing anastomosis and reconstruction across small and mid-size vessels — in cardiac, abdominal, thoracic, and reconstructive procedures — still rely on decades-old tools: dye injections and contact probes. Neither shows how blood is actually flowing.
ViewFlow's proprietary 20-dimensional vision algorithm reads blood flow the way a weather system reads the atmosphere — revealing dynamics no existing tool can see, in real time.
ViewFlow targets the same surgeons, same workflow, and same operating rooms as Novadaq — but without requiring dye injection. The precedent is already set.
ViewFlow integrates into existing surgical workflows without the added step — or risk — of dye injection.
Beyond binary yes/no — ViewFlow captures vorticity, shear stress, and mass transport in real time.
Hemodynamic data powers reduced-order models to predict surgical outcomes before the patient leaves the table.
A rare intersection of quantum-level physics, FDA-path experience, and clinical obsession — backed by advisors from the nation's top surgical institutions.
Jim builds technologies that make the invisible visible. A NASA fellow at Duke, his work has been licensed by Roche and Merck. He led cybersecurity at a Lockheed Martin national computing center.
ViewFlow is the culmination: an FDA surgical camera that shows surgeons how blood flows in real time — no dyes, no contact, no radiation. The last company in this space, Novadaq, sold to Stryker for $701M.
PhD and MBA, both from Duke.
Engaging with leading academic medical centers to reduce patient complications and become a future standard of care.
Real clinical validation. Real surgeon demand. A proven market playbook with a fundamentally better product.
